Royal Bank of Canada Sells 47,855 Shares of Thermo Fisher Scientific Inc. $TMO

Key Points

• Royal Bank of Canada reduced its stake in Thermo Fisher Scientific Inc. by 1.5% during the first quarter, selling 47,855 shares to hold approximately 0.85% of the company, worth about $1.6 billion.
• The company recently reported strong earnings of $5.36 per share, exceeding analysts' expectations, and recorded revenue of $10.86 billion in the last quarter.
• Thermo Fisher Scientific announced a quarterly $0.43 dividend, reflecting an annualized yield of 0.3%, with the dividend payout being scheduled for October 15th.

Royal Bank of Canada trimmed its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 1.5% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,224,676 shares of the medical research company's stock after selling 47,855 shares during the quarter. Royal Bank of Canada owned approximately 0.85% of Thermo Fisher Scientific worth $1,604,600,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently modified their holdings of the stock. Bernard Wealth Management Corp. acquired a new position in Thermo Fisher Scientific during the 4th quarter worth approximately $25,000. Ameriflex Group Inc. bought a new position in shares of Thermo Fisher Scientific during the fourth quarter valued at about $30,000. Keystone Global Partners LLC purchased a new stake in shares of Thermo Fisher Scientific during the 1st quarter valued at $31,000. IMA Advisory Services Inc. bought a new stake in shares of Thermo Fisher Scientific in the 1st quarter worth approximately $35,000. Finally, Smallwood Wealth Investment Management LLC purchased a new stake in Thermo Fisher Scientific in the 1st quarter worth about $37,000. Institutional investors and hedge funds own 89.23% of the company's stock.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 400 shares of the firm's stock in a transaction on Friday, July 25th. The stock was sold at an average price of $479.98, for a total transaction of $191,992.00. Following the transaction, the executive vice president directly owned 22,367 shares in the company, valued at $10,735,712.66. This trade represents a 1.76% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of the firm's stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $500.96, for a total value of $5,009,600.00. Following the sale, the chief executive officer directly owned 115,174 shares in the company, valued at approximately $57,697,567.04. The trade was a 7.99% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 28,896 shares of company stock worth $13,603,438 in the last 90 days. 0.33% of the stock is currently owned by insiders.

Thermo Fisher Scientific Stock Performance

Shares of NYSE TMO opened at $493.05 on Friday. Thermo Fisher Scientific Inc. has a 12-month low of $385.46 and a 12-month high of $627.88. The firm has a 50 day moving average of $452.50 and a 200 day moving average of $454.32. The firm has a market capitalization of $186.18 billion, a price-to-earnings ratio of 28.52, a price-to-earnings-growth ratio of 2.63 and a beta of 0.74. The company has a current ratio of 1.93, a quick ratio of 1.50 and a debt-to-equity ratio of 0.65.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.22 by $0.14. The business had revenue of $10.86 billion during the quarter, compared to analyst estimates of $10.68 billion. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.Thermo Fisher Scientific's revenue for the quarter was up 2.9% on a year-over-year basis. During the same quarter in the previous year, the company posted $5.37 earnings per share. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. On average, research analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date of this dividend is Monday, September 15th. Thermo Fisher Scientific's dividend payout ratio (DPR) is presently 9.95%.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on TMO. Wells Fargo & Company lowered their price target on shares of Thermo Fisher Scientific from $570.00 to $565.00 and set an "overweight" rating on the stock in a report on Thursday, July 24th. Hsbc Global Res cut shares of Thermo Fisher Scientific from a "strong-buy" rating to a "hold" rating in a research report on Thursday, July 24th. Robert W. Baird increased their target price on Thermo Fisher Scientific from $553.00 to $567.00 and gave the company an "outperform" rating in a report on Thursday, July 24th. UBS Group boosted their price target on Thermo Fisher Scientific from $460.00 to $500.00 and gave the company a "neutral" rating in a report on Thursday, July 24th. Finally, Scotiabank raised shares of Thermo Fisher Scientific from a "sector perform" rating to a "sector outperform" rating and set a $590.00 target price for the company in a research report on Friday, July 11th. Sixteen equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $593.00.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.